Quick summary: Taro Pharmaceuticals Canada Inc.'s Voluntary Recall of Docusate Sodium Capsules .
Taro Pharmaceuticals Canada Inc.'s Voluntary Recall of Docusate Sodium Capsules
Recommended action: compare your product with the official notice and follow the instructions published by the official source.
Recall details
Quick summary: Taro Pharmaceuticals Canada Inc.'s Voluntary Recall of Docusate Sodium Capsules .
Affected product details
Structured information extracted from the official recall notice. Confirm the identifiers and instructions in the original notice.
Affected products
Issue
Cronobacter (enterobacter) sakazakii is a bacteria that is a rare cause of serious or life-threatening infections, including meningitis and bloodstream infections, particularly in premature infants. Other vulnerable individuals include the elderly and those with weakened immune systems.
What you should do
- Consumers should speak to their healthcare practitioner if they or any of their family members have used this product.
- Taro Pharmaceuticals Canada Inc. is advising consumers to discontinue use of Docusate Sodium Capsules USP, 100 mg" (Lot # 31040225).
- Report any adverse reaction potentially related to these products to Health Canada (see below).
- Media and consumers should contact Taro Pharmaceuticals Canada Inc. at 1-800-268-1975 for more information.
Additional official information
Contains information licensed under the Open Government Licence – Canada. SafetyPulse is independent of the Government of Canada.
Frequently asked questions
Answers based on the official recall notice.
Product images
Official product images from Health Canada.
Starting...
Explore more
Related recalls
Similar recalls and safety notices.